Ozmosi | Rimonabant Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Rimonabant

Alternative Names: rimonabant, sr141716
Clinical Status: Inactive
Latest Update: 2025-12-10
Latest Update Note: News Article

Product Description

Mechanisms of Action: CB1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Healthy Volunteers|Obesity|Insulin Resistance|Inflammation|Overweight|Other|Atherosclerosis|Diabetes, Gestational|Dyslipidemia|Cocaine-Related Disorders|Obesity, Abdominal|Alcoholism

Phase 3: Type 2 Diabetes|Obesity|Glucose Intolerance|Prediabetic State|Other|Dyslipidemia|Tobacco Use Disorder|Smoking Cessation|Overweight|Atherosclerosis|Weight Loss|Myocardial Ischemia|Albuminuria|Coronary Artery Disease|Carotid Stenosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Obesity, Abdominal|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Stroke|Myocardial Infarction|Metabolic Syndrome X|Arteriosclerosis|Schizophrenia|Weight Gain|Prader-Willi Syndrome|Spinal Cord Injuries

Phase 2: Alcoholic Intoxication|Marijuana Abuse|Obesity|Spinal Cord Injuries|Polycystic Ovary Syndrome|Tobacco Use Disorder|Psychotic Disorders|Affective Disorders, Psychotic|Schizophrenia|Hypertension

Phase 1: Marijuana Abuse

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12618000263291p

2006-7041-83/hah

N/A

Not yet recruiting

Dementia

2018-11-26

2007-002492-14

MODERATO

N/A

Completed

Type 2 Diabetes|Dyslipidemia

2009-02-27

2022-03-12

Treatments

NCT01041170

06-DA-N410

P1

Completed

Marijuana Abuse

2010-01-11

2019-03-19

Treatments

NCT05622994

RIMOFATSCI-2

P2

Unknown status

Spinal Cord Injuries

2023-11-01

2024-11-02

Primary Endpoints|Treatments|Trial Status

NCT05398913

RIMOFATSCI-1

P2

Completed

Spinal Cord Injuries

2022-06-07

2022-11-16

NCT00656487

SCCAN

P2

Completed

Marijuana Abuse

2010-12-28

2019-03-18

Treatments

NCT00547118

HP-00041206

P2

Terminated

Tobacco Use Disorder|Affective Disorders, Psychotic|Psychotic Disorders|Obesity|Hypertension|Schizophrenia

2009-03-01

2019-11-05

Primary Endpoints|Treatments

2022-001522-30

2022-001522-30

P3

Active, not recruiting

Spinal Cord Injuries

2024-09-29

2008-002500-26

2008-002500-26

P3

Terminated

Type 2 Diabetes

2010-09-08

2022-03-12

Treatments

2008-001015-38

2008-001015-38

P3

Active, not recruiting

Schizophrenia

2010-07-23

2022-03-12

Treatments

2007-002077-31

EFFECTS

P3

Terminated

Type 2 Diabetes|Albuminuria

2009-07-22

2022-03-12

Treatments

2005-002942-20

CRESCENDO

P3

Withdrawn

Stroke|Obesity, Abdominal

2009-04-29

2022-03-12

Treatments

NCT00263042

CRESCENDO

P3

Terminated

Myocardial Infarction|Obesity, Abdominal|Stroke

2009-04-01

2019-03-21

NCT00228176

AUDITOR

P3

Terminated

Obesity|Arteriosclerosis|Atherosclerosis|Carotid Stenosis|Metabolic Syndrome X

2009-04-01

2019-03-21

Treatments

2006-005385-39

ALLEGRO

P3

Completed

Overweight

2009-03-04

2022-03-12

Treatments

NCT00325650

RAPSODI

P3

Terminated

Glucose Intolerance|Prediabetic State

2009-03-01

2019-03-21

Treatments

2007-004833-40

TOCCATA

P3

Terminated

Type 2 Diabetes

2009-02-18

2025-06-28

Treatments

2007-003012-61

STRONG

P3

Completed

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2009-02-27

2022-03-12

Treatments

NCT00546325

REASSURE

P3

Completed

Type 2 Diabetes|Overweight

2009-02-01

2019-03-21

NCT00576667

EFC10143

P3

Terminated

Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease

2009-02-01

2019-03-22

Treatments

2011-003104-20

Effec Acomplia gastric sensitivity

P4

Completed

Healthy Volunteers

2021-03-03

2022-03-13

Treatments

2008-005538-59

2008-005538-59

P4

Active, not recruiting

Cocaine-Related Disorders|Alcoholism

2011-02-18

2022-03-12

Treatments

2007-000907-13

RIGD

P4

Completed

Obesity, Abdominal|Diabetes, Gestational

2010-03-16

2022-03-12

Treatments

NCT00584389

EC/2006/117/PGMS

P4

Terminated

Obesity

2009-04-01

2019-03-22

Treatments

NCT00734123

PRIMARIA

P4

Unknown status

Atherosclerosis

2009-04-01

2019-03-18

Treatments